on TRANSGENE (EPA:TNG)
Results of the Transgene General Meeting of May 22, 2026
Transgene held its Combined General Meeting on May 22, 2026, at its headquarters in Illkirch-Graffenstaden. Chaired by Alessandro Riva, the meeting approved all the recommended resolutions, including the financial statements for the 2025 fiscal year and the "Say on Pay" vote. The terms of several directors were renewed, notably those of Sandrine Flory and Benoît Habert, for non-independent positions, as well as those of Emmanuelle Quilès and Carol Stuckley as independent directors.
Two new independent directors have been appointed: Dorothea Ledergerber, with expertise in pharmaceutical production, and Solange Peters, a specialist in oncology. Dorothea Ledergerber brings her experience in the pharmaceutical and biotechnology industry, while Solange Peters, at the CHUV (Lausanne University Hospital), contributes her oncology research.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news